Up­dat­ed: FDA ap­proves Zevra’s rare dis­ease drug af­ter re­sub­mis­sion

Af­ter a sec­ond re­view, the FDA ap­proved Zevra Ther­a­peu­tics’ treat­ment for Nie­mann-Pick dis­ease type C, a pro­gres­sive rare ge­net­ic dis­ease caused by the ac­cu­mu­la­tion of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER